The Institute for Bioscience and Biotechnology Research (IBBR) announces a newly funded five-year cooperative agreement with the National Institute of Standards and Technology (NIST) headed by the Co-Directors of IBBR, Dr. David J. Weber (PI) and Dr. John Marino (NIST). This award provides more than $3.3 million each year to support groundbreaking research, including technology and standards development that will impact vaccine and therapeutic discovery and development, and to improve access to life-saving treatments for addressing other crucial health challenges.
The Bacteriophage (Phage) Therapy (PT) market is growing rapidly in the U.S. The rise of antibiotic resistant bacteria and multidrug-resistant bacteria (MDRs) across the globe has increased the value and industry acceptance of a phage approach, which can help combat bacteria that cannot be effectively treated by antibiotics. What’s more, the phage modality is a great fit for targeted personalized medicine approaches.
Here’s Why the First Cure for HIV Could Emerge from Maryland These Five Life Science Organizations are Striving to Cure HIV November 5, 2019 For those that lived through the [….]
A Uniquely Positioned GMP BioManufacturing Facility Hits the Market in Maryland Biotech is booming across the country, especially in the top biotech clusters like Boston, San Francisco, New York and [….]
Biomanufacturing Institute Sets New Framework for Collaboration and New Model to Fund Innovation Biomanufacturing industry gathers at IBBR to learn about NIIMBL and funding opportunities Working together is not something [….]